FLT3 and acute myeloid leukemia: A significant decrease in the number of live cells at 72 hours was observed in all three treatment groups of a newly diagnosed FLT3-ITD AML sample (USC001) compared with A192-treated group (FLT3-A192 vs. A192, P = 0.009, 45% decrease; CD99-A192 vs. A192, P = 0.002, 51% decrease; Co-Assembled vs. A192, P < 0.0001, 67% decrease; Fig. 4J).